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Abstract
γ-Secretase is an aspartyl protease that cleaves multiple substrates that are involved in broad
biological processes ranging from stem cell development to neurodegeneration. The investigation
of γ-secretase has been limited by currently available assays that require genetic or biochemical
manipulation in the form of substrate transfection or membrane preparation. Here we report an
exo-cell assay that is capable of characterizing γ-secretase activity in any cellular system without
limitation. Using a highly active, recombinant substrate this assay can quickly and easily ascertain
the status of γ-secretase activity in cell systems and patient samples. We have applied this method
to determine the activity of γ-secretase in primary cell samples where transfection and/or
membrane isolation are not viable options. Importantly, it allows for the detection of real time γ-
secretase activity after inhibitor or drug treatment. The application of this assay to determine the
role of γ-secretase in physiological and pathological conditions will greatly facilitate our
characterization of this complex protease and help in the development and evaluation of γ-
secretase-targeted therapies in Alzheimer's disease or a variety of neoplasms.
Background
γ-Secretase is a multi-subunit protease that executes an
extraordinary cleavage of substrates within the lipid
bilayer. This process of target hydrolysis within the mem-
brane environment is known as regulated intramembrane
proteolysis (RIP) [1] whereby cleavage by γ-secretase
releases a protein fragment from its membrane tether that
can then transmit its signal. γ-Secretase was originally
identified as the enzyme responsible for cleavage of the
amyloid precursor protein (APP) [2]. Cleavage of APP
generates β-amyloid peptides that are believed to play a
causative role in the neuropathogenesis of Alzheimer's
disease [3] according to the "amyloid cascade hypothe-
sis." Additionally, it has been determined that γ-secretase
cleaves a multitude of other substrates that include the
Notch receptors [4], ErbB-4 [5], CD44 [6], as well as the
Notch ligands Delta-1 and Jagged-2 [7,8] amongst others.
Deregulated Notch signaling has been associated with the
development of various cancers, including T-cell Acute
Lymphoblastic Leukemia (T-ALL) [9]. Due to the central
role of γ-secretase in these pathologies, considerable
efforts have been made to characterize this unique pro-
tease.
Published: 2 June 2009
Molecular Neurodegeneration 2009, 4:22 doi:10.1186/1750-1326-4-22
Received: 2 April 2009
Accepted: 2 June 2009
This article is available from: http://www.molecularneurodegeneration.com/content/4/1/22
© 2009 Shelton et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Molecular Neurodegeneration 2009, 4:22 http://www.molecularneurodegeneration.com/content/4/1/22
Page 2 of 9
(page number not for citation purposes)
In order to better understand γ-secretase, in vitro assays
using purified exogenous recombinant substrate [10] or
assays utilizing isolated membrane from systems overex-
pressing substrate have been developed and reported
[11,12]. Currently, there are two predominant options to
study this protease in a cell line of interest: 1) stably trans-
fect the cell line with plasmids encoding APP, Notch or
other substrate fragments and conduct whole-cell based
detection assays, or 2) obtain large quantities of the cell
line and isolate the membrane fraction in a time-consum-
ing process. This can then be examined using an in vitro
assay that employs exogenous recombinant substrate as
mentioned previously. Due to these limitations, it is often
an extremely challenging task to quickly characterize γ-
secretase activity in multiple cell lines and primary cells.
Furthermore, it is currently impossible to examine the
real-time effect of various treatments on the status of γ-
secretase in cell systems without stable transfection. For
instance, treatment of a Notch-dependent cell line with γ-
secretase inhibitors may have an anti-proliferative effect,
but available methods cannot ascertain the extent of real-
time γ-secretase inhibition in the system. Therefore, devel-
opment of an assay that does not require transfection or
membrane preparation and is applicable for any cell type
has become an urgent issue for defining the relationship
of γ-secretase inhibition and its biological responses. This
is particularly critical to evaluate γ-secretase inhibitors
being used in preclinical and clinical studies because
assessment of target inhibition will facilitate the identifi-
cation and establishment of effective therapies. Recently,
we have determined that the use of biotinylated substrate
greatly enhanced substrate activity and assay sensitivity
over previous versions [13]. This prompted us to apply a
similar strategy to the development of a simplified γ-secre-
tase assay capable of quantifying real-time activity in cell-
based systems.
In this study we have developed a novel γ-secretase assay
that does not require membrane preparation and/or sub-
strate plasmid transfection. This γ-secretase assay that we
refer to as an "exo-cell" assay applies a highly active, bioti-
nylated recombinant substrate (Sb4) of γ-secretase exoge-
nously to cells in the presence of a small quantity of
CHAPSO detergent. We have found that this 96-well assay
format can detect γ-secretase activity from as little as a few
thousand cells. Furthermore, we can easily detect γ-secre-
tase activity from primary B-cell Chronic Lymphocytic
Leukemia (B-CLL) cells isolated from patients. More
importantly, this assay can monitor the real-time γ-secre-
tase activity in a 96-well format after inhibitor treatment
and has allowed us to establish a correlation between the
anti-proliferative effect of γ-secretase inhibitors against
lymphoma cells and real-time reduction in γ-secretase
activity. Taken together, the development of this novel
assay allows for the characterization of real-time γ-secre-
tase activity directly in cell lines as well as primary patient
samples. This assay will simplify the study of γ-secretase
and provide new tools in the characterization of this
enzyme as well as facilitate the development of therapies
against Alzheimer's disease and Notch-dependent neo-
plasms. Furthermore, the application of this simplified
method will greatly enhance our ability to examine this
unique enzyme and advance our understanding of γ-secre-
tase biology.
Results
Development of an exo-cell γ-secretase assay using a 
biotinylated recombinant APP substrate
We recently demonstrated that it was possible to directly
biotinylate a γ-secretase peptide substrate to be utilized in
an in vitro assay [13]. Here, we have designed a truncated,
recombinant APP protein that is directly biotinylated dur-
ing overproduction in Eschericia coli. This substrate is
highly active and offers an advantage to develop an easy
and sensitive γ-secretase assay. This allows for the elimina-
tion of stable transfection of γ-secretase substrate into the
cell line of interest or isolation of membrane from large
numbers of cells that can then be examined using an in
vitro γ-secretase assay.
Briefly, this recombinant substrate was based on a trunca-
tion of the APP substrate that encompassed the 76 C-ter-
minal amino acids of APP. To this truncation, a maltose-
binding protein (MBP) tag was cloned to assist with puri-
fication. Finally, an Avitag was also cloned onto the N-ter-
minus of truncated APP (Fig. 1a). This avitag provides a
mechanism whereby the recombinant protein can be
directly biotinylated during over-expression in Eschericia
coli. During induction of protein expression, biotin was
added so that biotin ligase directly incorporated biotin
into the recombinant γ-secretase substrate. This bioti-
nylated recombinant substrate is referred to as Sb4 and
was purified using an amylose resin column. After the
recombinant protein was isolated, the sample was ana-
lyzed by LC-MS (Fig. 1b). The analysis showed that there
were two species with molecular masses of 12,053 and
12,279, which correlated to non-biotinylated and bioti-
nylated forms of substrate (calculated molecular masses
were 12,050 and 12,276, respectively). Furthermore, it
was determined that approximately 90% of purified Sb4
was biotinylated. We next attempted to apply the highly
active Sb4 substrate to develop an assay capable of quan-
tifying γ-secretase activity directly in cultured cells that
would eliminate the need for stable transfection of sub-
strate into cells or the isolation of membrane from large
quantities of the cell line of interest.
In order to assay γ-secretase activity in cells, an exo-cell
assay was designed that would allow for the evaluation of
γ-secretase in real-time under diverse treatment condi-Molecular Neurodegeneration 2009, 4:22 http://www.molecularneurodegeneration.com/content/4/1/22
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tions. Previously, Li et al. [10] had determined that in an
in vitro γ-secretase assay, CHAPSO was superior to other
detergents for promoting activity. Therefore, HeLa cells
were first incubated with Sb4 substrate, as well as
CHAPSO detergent as depicted in Fig. 1c. Specifically,
HeLa cells were seeded in a 96-well plate and allowed to
attach overnight. Then, media was removed, cells were
washed once in PBS, and fresh media was added back con-
taining 1 μM Sb4 substrate and CHAPSO detergent. The
reaction mixture was incubated for 2.5 hours at 37°C.
After cell debris was pelleted down by centrifugation, the
resulting supernatant was used to examine γ-secretase-
mediated product formation with G2-10 antibodies (Fig
1c). The amount of CHAPSO required for assaying activity
in cells was first titrated, and it was determined that repro-
ducible γ-secretase activity was detected within a range
from 0.15% CHAPSO to an upper limit as high as 0.3%
detergent. However, the greatest amount of activity was
detected by using 0.25% CHAPSO (Fig. 2a), which is con-
sistent with findings in a previously reported in vitro assay
[10]. The activity at each of these concentrations could be
attributed to γ-secretase in the HeLa cells as treatment
Recombinant γ-secretase substrate allows for detection of protease activity directly in cells Figure 1
Recombinant γ-secretase substrate allows for detection of protease activity directly in cells. (a) Sb4 γ-secretase 
substrate. Schematic of the truncated Sb4 substrate from the amyloid precursor protein that has an engineered MBP tag as well 
as Avitag for purification and biotinylation, respectively. A thrombin cleavage site between the MBP tag and avitag allows for 
the removal of MBP by thrombin treatment following substrate purification. (b) LC-MS analysis identified Sb4 at the expected 
size and determined that greater than 90% of purified Sb4 is shown to be biotinylated. (c) Development of an exo-cell assay. 
Utilization of the Sb4 substrate in conjunction with a small amount of CHAPSO detergent allows for real-time examination of 
γ-secretase activity directly from cells using ECL or homogenous time-resolved fluorescence (HTRF) detection methods in 96-
well format.
a
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with GSI abrogated cleavage of Sb4 (data only shown for
0.25% CHAPSO, Fig. 2a). Next, the sensitivity of the assay
was evaluated by determining the lower limit of HeLa cell
numbers needed to detect γ-secretase activity. The sensitiv-
ity of this assay was able to distinguish reproducible pro-
tease activity from as little as 2,500 HeLa adenocarcinoma
cells with a signal to noise ratio greater than 5:1 (Fig. 2b).
However, detectable activity was cell number dependent
increasing from 1000 HeLa cells to 10,000 cells with the
greatest activity found using 10,000 HeLa cells which pro-
duced a signal to noise ratio of approximately 125:1. The
signal reaches its maximal amount at 10,000 HeLa cells
and levels off at 20,000 HeLa cells due to the limiting sub-
strate concentration in the assay.
Evaluation of distinct γ-secretase inhibitors in the exo-cell 
assay
Next, we examined the potency of various γ-secretase
inhibitors in the exo-cell assay and compared the IC50 val-
ues to those from comparable in vitro and whole cell-
based assays (Fig. 3). A range of inhibitors were assayed
that included the benzodiazepine Compound E and a sul-
Development of an exo-cell assay for quantification of γ-secretase activity in cells Figure 2
Development of an exo-cell assay for quantification of γ-secretase activity in cells. (a) Titration of CHAPSO deter-
gent in the exo-cell assay. CHAPSO detergent was titrated to determine the optimal amount required for stimulating γ-secre-
tase activity. The titration was performed using 10,000 HeLa cells and 1 μM Sb4 substrate. This reaction was incubated for 2.5 
hours at 37°C. Supernatent was then collected and analyzed using ruthenylated G2-10* antibody. Activity was quantitated by 
measuring ECL. For each assay point n = 4, and s.d. is plotted. (b) Titration of the number of HeLa adenocarcinoma cells from 
which the exo-cell assay can detect γ-secretase activity. The indicated number of HeLa cells were seeded in a 96-well plate and 
allowed to attach overnight. The next day media was removed and replaced with fresh media containing 0.25% CHAPSO 
detergent, 1 μM Sb4 substrate, and DMSO or 1 μM Compound E to define background. Values plotted represent the activity 
quantified for each cell number assay point with GSI-defined background subtracted. For each assay point n = 4, and s.d. is plot-
ted. (c) Dose-dependent inhibition of γ-secretase activity by GSI-34. HeLa cells were seeded 10,000 cells per well of 96-well 
plate. The cells were treated for 24 hours with the indicated concentration of GSI-34 inhibitor. Cells were then washed once 
with PBS and then the exo-cell assay was performed using 1 μM Sb4 substrate and 0.25% CHAPSO detergent. (d) IC50 values 
of distinct GSIs in extended exo-cell assay. IC50 values were obtained for 2 distinct GSI compounds using the extended exo-cell 
assay. For each data point n = 3, and s.d. is plotted.
ab
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fonamide-based inhibitor referred to as GSI-34. These
compounds all inhibit γ-secretase in the nanomolar range
in our in vitro assay and their IC50 values are slightly ele-
vated in the exo-cell assay (Fig. 3). It is worth noting that
while the presented data employs ECL detection of
cleaved substrate, we also successfully used homogeneous
time-resolved fluorescence (HTRF) technology to detect
cleaved substrate in our exo-cell assay (calculated IC50 val-
ues for Compound E and GSI-34 were 3.8 nM and 5.9 nM,
respectively, using ECL. They were 5.4 nM and 5.4 nM
using HTRF detection in the exo-cell assay).
Detection of real-time γ-secretase inhibition
γ-Secretase inhibitors are currently being used as molecu-
lar probes and are being evaluated as potential therapeu-
tics in Alzheimer's disease as well as for various neoplasms
like T-cell acute lymphoblastic leukemia where γ-secre-
tase-mediated Notch signaling is tumorigenic. We next
modified the exo-cell assay so that our system can moni-
tor real-time γ-secretase activity and inhibition. After HeLa
cells were incubated with varying concentrations of GSI-
34 or Compound E for 24 hours, media was removed and
the cells were washed to remove excess unbound inhibi-
tor. Fresh media containing only CHAPSO detergent and
Sb4 substrate were placed back onto the cells and the exo-
cell assay was then conducted as previously described.
HeLa cells that were treated in this manner with GSI-34
show a dose-dependent inhibition of γ-secretase activity
(Fig. 2c). This modified, extended treatment exo-cell assay
is capable of quantifying remaining γ-secretase activity fol-
lowing drug treatment on virtually any cell type. The IC50
values for Compound E and GSI-34 were calculated using
the extended exo-cell assay (Fig. 2d and Fig. 3). Compar-
ing the potency of these unique GSIs in currently estab-
lished  in vitro and cell-based assays reveals that the
extended exo-cell assay more closely mimics that wit-
nessed in a cell-based γ-secretase assay that uses N2A
mouse neuroblastoma cells stably expressing the APP sub-
strate (N2A-APP) (Fig. 2d and Fig. 3). The IC50 values for
Compound E and GSI-34 in the extended exo-cell assay
were 2.83 nM and 38.7 nM respectively (Fig. 2d and Fig.
3) as compared to 4.6 nM and 32.4 nM, respectively, in
the cell-based assay (Fig. 3) – both GSIs exhibited
decreased potency in the cell-based and extended exo-cell
assays as compared to their respective in vitro values.
Regardless, the trend of decreasing potencies of GSIs in
the extended exo-cell assay is similar to that witnessed in
the stable N2A-APP cell-based system and this is likely
due to the GSIs being incubated for 24 hours in the pres-
ence of a cellular environment that can affect compound
half-life amongst other factors. These data show that our
exo-cell assay can be used to evaluate the real-time status
of γ-secretase activity in cell lines in a simple and sensitive
manner.
Potency of γ-secretase inhibitors in various activity assays Figure 3
Potency of γ-secretase inhibitors in various activity assays. The potency of two structurally unique GSIs was assayed in 
four unique γ-secretase activity assays. IC50 values were determined from the dose response curves using a non-linear regres-
sion analysis in the Prism software. An in vitro assay was based on the one previously reported by Li et al. [10], except we uti-
lized Sb4 substrate that eliminated the need for biotinylated antibody. The cell-based activity assay used N2A mouse 
neuroblastoma cells stably over-expressing APP and a biotinylated 4G8 antibody that binds the C-terminus of the β-amyloid 
peptide. The exo-cell assay incubated HeLa cells simultaneously with GSI, Sb4 substrate as well as 0.25% CHAPSO detergent 
prior to detecting substrate cleavage. Finally, the extended exo-cell assay first incubated HeLa cells with GSI for 24 hours. Sub-
sequently, the cells were washed 1× in PBS and then incubated with Sb4 substrate and CHAPSO detergent. The assay was then 
carried out exactly as described for the original exo-cell method. All assays incorporate ruthenylated G2-10* antibody to 
detect 40-site cleavage of APP or recombinant Sb4 substrate and quantitated activity by measuring ECL.
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Clearly, the extended exo-cell assay can be applied to
quickly and efficiently quantitate the γ-secretase activity
from any cultured cells in real-time. As such, we set out to
utilize this novel assay to ascertain whether there exists a
correlation between inhibition of γ-secretase and inhibi-
tion of cellular proliferation in a γ-secretase-dependent
lymphoma line. Notch receptors require γ-secretase
processing to release an intracellular fragment that trans-
locates into the nucleus to transmit its signal. Multiple
lymphoma lines have been shown to be dependent upon
γ-secretase activity [14,15]. We have determined that the
A20 mouse lymphoma line is sensitive to γ-secretase inhi-
bition by GSI compounds (Fig. 4a) following 48 hours of
treatment. Furthermore, we establish that there is a detect-
able correlation between this inhibition of cellular prolif-
eration in A20 cells and inhibition of γ-secretase.
Treatment of the A20 cell line with the three structurally
unique, small molecule GSIs L-685,458, Compound E,
and GSI-34 were all able to inhibit cellular proliferation
(Fig. 4a for GSI-34; L-685,458 and Compound E data not
shown) likely eliminating the possibility of an off-target,
non-γ-secretase related effect. Interestingly, the data in Fig.
4a suggests that a small amount of remaining γ-secretase
activity is sufficient to maintain cellular proliferation in
this particular model system. For instance, 300 nM GSI-34
is able to inhibit approximately 80% of γ-secretase activ-
ity, yet this concentration only reduces cellular prolifera-
tion by 30% in the A20 mouse lymphoma model system.
This data may help to explain the common finding that
therapeutic levels of GSIs required to inhibit proliferation
of Notch-dependent neoplastic cell lines are often far
greater than in vitro IC50 values.
Quantification of real-time γ-secretase activity in primary 
tumor samples
Lastly, it was not known whether this exo-cell method
could be used to measure activity in primary samples from
patients. Peripheral primary B-cell chronic lymphocytic
leukemia cells (B-CLL) are arrested in the G0 phase of the
cell cycle [16] and this condition makes it very difficult to
assay γ-secretase activity in these primary cell samples.
Additionally, it has been shown that Notch2 plays a role
in the overexpression of CD23 in B-CLL and this may be
related to the development of this neoplasm [17]. There-
fore, the study of γ-secretase and Notch with regard to B-
CLL biology has recently become an urgent issue. Stable
transfection of substrate into a non-proliferating cell line
is not a practical option and isolating enough B-CLL cells
from a patient to prepare membrane fractions for use in in
vitro assays is not feasible. However, the exo-cell assay
now allows for the determination of protease activity
quite easily. We have quantitated activity from three sepa-
rate B-CLL patient samples and defined background activ-
ity for the assay in the presence of 1 μM Compound E (Fig.
4b) from 50,000 total B-CLL cells. Using the exo-cell assay
we have been able to characterize γ-secretase activity in B-
CLL patient samples for the first time. This previously
would have been nearly impossible, but this assay makes
it simple to detect protease activity in troublesome B-CLL
patient samples in a few hours.
Discussion
The application of our new exo-cell assay will have wide-
ranging implications for the study of γ-secretase. While
extensive efforts to characterize this protease have already
been put forth due to its connection to Alzheimer's dis-
ease as well as numerous cancers, technical difficulties
associated with the study of membrane enzymology has
hindered much progress. The presented exo-cell assay will
simplify the investigation of γ-secretase across different
cell lines and tissue types as well as following diverse treat-
ment conditions. Furthermore, this assay is able to effi-
ciently evaluate the real-time status of γ-secretase from
primary patient samples and completely eliminates the
need for stable transfection of substrate or isolation of
membrane. Not only will the quantification of protease
activity in various cell lines now be simple, but this novel
assay also provides a rapid means for evaluating the effi-
cacy of potential therapeutics that affect γ-secretase in
their target environment. For instance, γ-secretase inhibi-
tors could previously be screened using in vitro assays
against membrane isolated from the target cell line or tis-
sue they were being used to treat, however, the real-time
γ-secretase activity remaining in this system could not
readily be evaluated following treatment. This is now an
easy process that can be applied to nearly any cell line or
tissue type and will require a nominal number of cells to
do so. We are able to detect significant γ-secretase activity
from as few as 2,500 HeLa adenocarcinoma cells using
0.25% CHAPSO detergent concentration. The detection
of real-time activity is a significant development due to
the central role of γ-secretase in numerous biological sig-
naling pathways as well as in various disease states. Previ-
ously, it was impractical to evaluate γ-secretase activity in
a system following cellular manipulation, however the
exo-cell assay provides a simple means to assess the effect
of GSI-application or other treatments on γ-secretase
activity. Interestingly, we have shown that in a γ-secretase-
dependent lymphoma line, cellular proliferation can be
maintained by a minimal fraction of remaining γ-secre-
tase activity. This finding may help to clarify why thera-
peutic concentrations of GSIs against lymphoma and
other systems sensitive to inhibition of γ-secretase far
exceed their calculated in vitro IC50 values. The real-time
exo-cell assay simplifies the study of γ-secretase in diverse
systems and will greatly facilitate the evaluation and
development of novel therapies against Alzheimer's dis-
ease and cancers where γ-secretase plays a tumorigenic
role as well as allow for the investigation of γ-secretaseMolecular Neurodegeneration 2009, 4:22 http://www.molecularneurodegeneration.com/content/4/1/22
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Figure 4 (see legend on next page)
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biology in systems where examination was not previously
possible.
Methods
Production of γ-secretase recombinant substrate
Briefly, a DNA fragment encompassing amino acids 620–
695 of the 695-aa isoform of APP as well as a maltose
binding protein tag was cloned into the pIAD16 prokary-
otic vector [18]. Additionally, there was an Avitag also
incorporated into this vector. Avitag, a specific 15-residue
peptide, is recognized by biotin ligase that specifically cat-
alyzes an attachment of biotin to the lysine residue within
the Avitag. The protein was then co-expressed in Eschericia
coli with the pACYC184 biotin ligase plasmid. IPTG at 0.1
mM was used to induce expression of Sb4 as well as biotin
ligase at 20°C for 5 hours in the presence of 50 μM biotin.
Biotin ligase directly biotinylates the avitag during protein
expression. Sb4 was ultimately purified using an amylose
resin column, eluted with excess maltose and thrombin-
cleaved to remove maltose-binding protein from the puri-
fied substrate. The biotinylation of recombinant substrate
was confirmed by LC-MS.
Real-time exo-cell γ-secretase activity assay
Cells were seeded at their indicated concentration in 96-
well plates and allowed to attach overnight (Fig. 1c). The
next day, media was removed and cells were washed once
with PBS. Fresh media was then added containing 0.25%
CHAPSO detergent, Sb4 substrate to a final concentration
of 1 μM, and 1% DMSO or γ-secretase inhibitor. This was
incubated for 2.5 hours at 37°C. Media was removed and
cell debris was pelleted from this media for 5 min. at
3,500 rpm's. Supernatant was then added to ruthenylated
G2-10* antibody that recognizes cleaved product, but not
uncleaved substrate. This was incubated for an additional
2 hours at room temperature. Finally, magnetic streptavi-
din beads were added to a final concentration of 80 μg/ml
and incubated for 30 min. at room temperature. Assay
buffer was added to the samples and γ-secretase-mediated
cleavage of substrate was monitored using electrochemi-
luminescence (ECL) [10]. Protocol for HTRF detection
can be found below.
Conversely, an extended exo-cell assay was performed
whereby cells were seeded and allowed to attach over-
night as previously described. However, the next day
media was removed and replaced with fresh media con-
taining 1% DMSO or γ-secretase inhibitor. These were
incubated for 24 hours at 37°C. Following this incuba-
tion, the cells were washed once with PBS and fresh media
containing detergent and substrate were added. From this
point on, the exo-cell assay as described above was fol-
lowed.
Homogeneous time-resolved fluorescence (HTRF) was
also incorporated for the exo-cell assay detection of
cleaved substrate. The exo-cell assay proceeded as previ-
ously described except that media supernatent was col-
lected and 10 μl of supernatent was added to 10 μl of
HTRF detection mix. The HTRF detection mix contained 1
nM G2-10 antibody, 2 nM anti-mouse IgG cryptate entity
and 15 nM Streptavidin-XL665 flourophore. These were
all dissolved in HTRF detection buffer which was 50 mM
phosphate buffer, pH 7.0, 0.2% BSA and 0.8 M potassium
fluoride. Exo-cell supernatent and HTRF detection mix
were incubated together for 5 hours in a 384-well plate
and then activity was measured by stimulating at 337 nm
and reading at 665 nm.
In vitro and cell-based γ-secretase assays
The  in vitro and cell-based γ-secretase assays were per-
formed similarly as previously described [10]. Briefly, the
recombinant Sb4 substrate was incubated for 2.5 hours at
37°C in pH 7.0 PIPES buffer in the presence of 0.25%
CHAPSO detergent and solubilized γ-secretase at a final
concentration of 40 ng/ul. The detection of cleaved sub-
Examination of real-time γ-secretase activity in A20 lymphoma and in primary B-CLL patient samples Figure 4 (see previous page)
Examination of real-time γ-secretase activity in A20 lymphoma and in primary B-CLL patient samples. (a) Cor-
relation between real-time inhibition of γ-secretase activity and GSI-mediated inhibition of A20 mouse lymphoma proliferation. 
Two 96-well plates were seeded with 50,000 A20 mouse lymphoma cells per well in 100 μl RPMI media. To each of these 
plates an additional 100 μl of media was added containing DMSO or GSI-34 to indicated final concentration. These plates were 
incubated for 48 hours at 37°C. Following this incubation, one plate was used in a real-time exo-cell assay to quantitate the 
real-time inhibition of γ-secretase in A20 cells. Briefly, A20 cells were pelleted and media removed. Fresh media containing 1 
μM Sb4 substrate and 0.25% CHAPSO detergent were added and the exo-cell assay was performed. For each assay point n = 
4, and s.d. is plotted. Additionally, to the other 96-well plate 2 μCi/ml [3H]thymidine was incubated with the cells for 5 hours. 
Following 5-hour incubation at 37°C, the amount of tritiated DNA was quantified on a β-counter. For each proliferation assay 
point n = 10, and s.d. is plotted. (b) Real-time γ-secretase activity in primary B-CLL patient samples. B-CLL cells were seeded in 
96-well plate at a concentration of 50,000 cells per well. These were allowed to attach overnight. Subsequently, the media was 
removed and fresh media was added back that contained either DMSO or 1 μM Compound E inhibitor. This was incubated for 
24 hours at 37°C. Cells were then washed once in PBS and exo-cell assay was performed as previously described. For each 
assay point n = 4, and s.d. is plotted.Molecular Neurodegeneration 2009, 4:22 http://www.molecularneurodegeneration.com/content/4/1/22
Page 9 of 9
(page number not for citation purposes)
strate was determined using ruthenylated G2-10* anti-
body. Due to biotinylation of the Sb4 substrate, this
eliminated the additional use of 6E10 biotinylated anti-
body from the original protocol.
The cell-based assay utilized N2A mouse neuroblastoma
cells that stably overexpress the amyloid precursor pro-
tein. These were incubated with γ-secretase inhibitors in a
final concentration of 1% DMSO for 24 hours. Following
incubation, the supernatant was removed from the cells
and assayed for Aβ 40-site cleaved APP product using
ruthenylated G2-10* antibody as well as biotinylated 4G8
antibody.
Lymphoma proliferation assay
A20 mouse lymphoma cells were seeded in a 96-well plate
at a concentration of 5 × 105 cells/ml in 100 μl RPMI
media containing 2% fetal bovine serum. An additional
100 μl of media containing DMSO or γ-secretase inhibitor
was added and incubated for 48 hours at 37°C. After this
incubation, the cells were incubated for 5 hours with 2
μCi/ml [3H]thymidine at 37°C. Proliferative response was
then evaluated by harvesting the tritiated DNA from cells
using a Skatron cell harvester and proliferation assessed as
a function of [3H]thymidine incorporation measured on a
β-counter.
Primary B-CLL patient sample isolation
Primary samples were obtained from patients diagnosed
with B-cell chronic lymphocytic leukemia who were
untreated. Written informed consent was obtained from
each patient in accordance with the guidelines of the Insti-
tutional Review Board of Memorial Sloan Kettering Can-
cer Center and the Declaration of Helsinki. Peripheral
blood mononuclear cells (PBMCs) were isolated using
standard Ficoll-Hypaque density gradient and subse-
quently stored in liquid nitrogen. Prior to use in assay,
samples were thawed and resuspended in RPMI media
and allowed to attach overnight at 37°C. The extended
exo-cell assay was then performed as described above.
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